Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1433-0458
    Keywords: Schlüsselwörter Hörsturz ; Progrediente Innenohrschwerhörigkeit ; Phospholipid-Antikörper ; Serotonin-Antikörper ; Gangliosid-Antikörper ; Key words Sudden deafness ; Progressive hearing loss ; Phospholipid antibodies ; Serotonin antibodies ; Ganglioside antibodies
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Immunoserological assays of patients with sudden deafness and progressive hearing losses have revealed the presence of different antibodies, leading to the assumption that immunological processes may be involved. Recent investigations have demonstrated that these patients have phospholipid antibodies that can cause venous or arterial vasculopathies. In the present study we analyzed the incidence of these antibodies in patients with inner ear disorders. Sera of 55 patients with sudden deafness and 80 patients with progressive hearing loss were tested. Phospholipid antibodies were demonstrable in 49% of the patients with sudden hearing loss and 50% of the patients with progressive hearing loss. Serotonin and ganglioside antibodies were found in 53% of the patients with sudden hearing loss and 63% of the patients with progressive hearing loss. Since these three antibodies are also frequently found in patients with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS), 28 of the patients studied displayed symptoms typical for these disorders, including fatigue, myalgia, arthralgia, depressions, sicca symptoms and diarrhea. We now recommend questioning patients suffering from inner ear disorders for symptoms typical for FMS or CFS, since these diseases are often closely related to inner ear disorders. If symptoms are present, antibodies should be tested against phospholipids, serotonin and gangliosides. If present, the antibodies are diagnostic for each syndrome. Additionally these immunologic and serologic findings show that these antibodies may play a role in the etiology of hearing loss disorders.
    Notes: Zusammenfassung Bei Patienten mit Hörsturz und progredienter Innenohrschwerhörigkeit sind verschiedene Autoantikörper nachgewiesen worden, so daß auch immunologische Prozesse als Ursachen dieser Erkrankungen diskutiert werden. In jüngster Zeit entdeckte man bei einem Teil dieser Patienten Antikörper gegen Phospholipide, die venöse oder arterielle Vaskulopathien verursachen können. Da bei Innenohrstörungen auch Durchblutungsstörungen angenommen werden, wurde geprüft, ob sich diese Antikörper gehäuft bei Patienten mit dieser Erkrankung finden lassen. Untersucht wurden 55 Patienten mit Hörsturz und 80 Patienten mit progredienter Innenohrschwerhörigkeit (IOS). Antikörper gegen Phospholipide (APA) ließen sich bei 49% der Patienten mit Hörsturz und 50% der Patienten mit progredienter IOS nachweisen. Gleichzeitig wurden auch Antikörper gegen Serotonin und Ganglioside bestimmt, die bei 53% der Patienten mit Hörsturz und 63% der Patienten mit progredienter IOS festgestellt wurden. Diese drei Antikörper werden vor allem bei Patienten mit Fibromyalgiesyndrom (FMS) oder Chronic-fatigue-Syndrom (CFS) beobachtet; 28 von 46 befragten Patienten litten unter den für diese Erkrankungen typischen Symptomen, wie u.a. Müdigkeit, Gelenk- und Muskelschmerzen, Depressionen, Sicca-Symptomatik und Diarrhö. Für die Praxis ist es empfehlenswert, bei Patienten mit akuter und chronischer IOS routinemäßig nach FMS/CFS-relevanten Begleitsymptomen zu fragen, da diese Erkrankungen mit einer IOS einhergehen können. Bei positiver Anamnese sollte die Bestimmung obiger Antikörper erfolgen, durch deren Nachweis die Verdachtsdiagnose wahrscheinlicher gemacht werden kann.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1041
    Keywords: Agranulocytosis ; OPC-8212 ; quinolinone derivative ; 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone ; bone-marrow progenitor cells
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212) is a quinolinone derivative with positive inotropic properties. In order to elucidate the effect of OPC-8212 on the haemopoietic system we studied its in vitro effect on bone-marrow progenitor cells (granulocyte/monocyte colonyforming units [CFU-GM] and erythroid burst-forming units [BFU-E]), on the proliferation and secretion of granulocyte/monocyte colony-stimulating factor (GM-CSF) and interferon-γ (IFN-γ) by peripheral lymphocytes, and on GM-CSF secretion by fibroblasts from healthy individuals. The dose-effect relations of OPC-8212 on CFU-GM proliferation and on lymphocytic GM-CSF secretion showed no effect at very low drug concentrations, with a threshold at the lower end of the therapeutic range and highly significant dose-dependent inhibition at concentrations above that threshold. BFU-E, peripheral lymphocyte proliferation and lymphocytic IFN-γ secretion were depressed, although to a lesser extent, in a linear dose-dependent fashion. OPC-8212 did not affect GM-CSF secretion by one strain of fibroblasts but reduced it at higher concentrations in assays with another strain of cells. We conclude that direct toxic effects on bone-marrow progenitor cells, in combination with the inhibition of cytokines involved in the regulation of haemopoiesis in certain susceptible individuals, may be responsible for idiosyncratic reactions to OPC-8212.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...